

1 **Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India**

2 Seth A. Hoffman^{1,*}, Christopher LeBoa^{1,a}, Kashmiri Date^{2,b}, Pradeep Haldar³, Pauline Harvey^{4,c}, Rahul
3 Shimpi⁴, Qian An², Chenhua Zhang², Niniya Jayaprasad^{4,d}, Lily Horng¹, Kirsten Fagerli², Priyanka Borhade⁴,
4 Debjit Chakraborty⁵, Sunil Bahl⁶, Arun Katkar⁴, Abhishek Kunwar⁴, Vijay Yewale⁷, Jason R. Andrews¹,
5 Pankaj Bhatnagar⁴, Shanta Dutta⁵, Stephen P. Luby¹

6

7 ¹ Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University
8 School of Medicine, Stanford, California, USA; ² Global Immunization Division, Center for Global Health,
9 Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ³ Ministry of Health & Family Welfare,
10 Government of India, New Delhi, India; ⁴ World Health Organization-Country Office for India, National
11 Public Health Surveillance Project, New Delhi, India; ⁵ National Institute of Cholera and Enteric Diseases,
12 Indian Council of Medical Research, Kolkata, India; ⁶ World Health Organization South-East Asia Regional
13 Office, New Delhi, India; ⁷ Dr. Yewale Multispecialty Hospital for Children, Navi Mumbai, India

14 ^a Current affiliation: Division of Environmental Health Sciences, School of Public Health, University of
15 California, Berkeley, California, USA; ^b Current affiliation: Johnson & Johnson Global Public Health, New
16 Brunswick, New Jersey, USA; ^c Current affiliation: U.S. Centers for Disease Control and Prevention,
17 Gaborone, Botswana; ^d World Health Organization, India Hypertension Control Initiative, New Delhi,
18 India

19 Keywords: typhoid fever, *Salmonella* Typhi, vaccines, global health, India

20

21 Running Title: Typhoid Vaccine Campaign Effectiveness

22

23 ***Corresponding Author:**

24 Seth A. Hoffman, M.D.

25 Division of Infectious Diseases & Geographic Medicine, Stanford University School of Medicine

26 300 Pasteur Drive, Stanford, CA 94305 USA

27 Lane Building, 134

28 Tel: +1-650-725-8338 | Fax: +1-650-498-9876

29 Email: sethhoffman@stanford.edu

30

31 Alternate corresponding author:

32 Stephen P. Luby, M.D.

33 Stanford University

34 Yang and Yamazaki Environment and Energy Building

35 473 Via Ortega, Stanford, CA 94305 USA

36 Tel: +1-650-723-4129 | Fax: +1-650-725-3402

37 Email: sluby@stanford.edu

38

39 **40 Word Summary:** In 2018, the Navi Mumbai Municipal Corporation conducted a typhoid conjugate

40 vaccine campaign in half of its communities. Utilizing a test-negative design, we estimate that this

41 campaign reduced typhoid risk by 56% (25-74%) in vaccinated communities compared to non-campaign

42 communities.

43

44

45

46

47 **ABSTRACT**

48 **Background:** The WHO recommends vaccines for prevention and control of typhoid fever, especially
49 where antimicrobial-resistant typhoid circulates. In 2018 the Navi Mumbai Municipal Corporation
50 (NMMC), implemented a TCV campaign. The campaign targeted all children aged 9-months through 14-
51 years within NMMC boundaries (~320,000 children) over 2 vaccination phases. The phase 1 campaign
52 occurred from July 14-August 25, 2018 (71% coverage, ~113,420 children). We evaluated the campaign's
53 programmatic effectiveness in reducing typhoid cases at the community level.

54 **Methods:** We established prospective, blood culture-based surveillance at 6 hospitals in Navi Mumbai,
55 offering blood cultures to children presenting with fever for at least 3 days. We employed a cluster-
56 randomized test-negative design to estimate the effectiveness of the vaccination campaign on pediatric
57 typhoid cases. We matched culture-confirmed typhoid cases with up to 3 culture-negative controls by
58 age and date of blood culture and assessed community vaccine campaign phase as an exposure using
59 conditional logistic regression.

60 **Results:** Between September 1, 2018–March 31, 2021, we identified 81 typhoid cases and matched
61 these with 238 controls. Cases were 0.44 times as likely to live in vaccine campaign communities
62 (campaign effectiveness, 56%, 95%CI: 25%-74%, p=0.002). Cases ≥ 5-years-old were 0.37 times as likely
63 (95% CI: 0.19-0.70; p-value = 0.002) and cases during the first year of surveillance were 0.30 times as
64 likely (95% CI: 0.14-0.64; p-value = 0.002) to live in vaccine campaign communities.

65 **Conclusions:** Our findings support the use of TCV mass vaccination campaigns as effective population-
66 based tools to combat typhoid fever.

67

68

69

70

71

72 **INTRODUCTION**

73

74 Typhoid fever, caused by *Salmonella enterica* subspecies *enterica* serovar Typhi (*S. Typhi*),
75 remains the cause of a significant burden of disease, with an estimated over 11 million cases and
76 116,000 deaths in 2017, the majority of which occurred in children under 15 years of age [1]. In the mid-
77 20th century typhoid fever mortality dropped significantly, from upwards of 12% in the pre-antibiotic era
78 [2], to approximately one percent in most areas after the introduction of effective antibiotics [3, 4].
79 Unfortunately, antimicrobial-resistant *S. Typhi* is on the rise, especially in Asia [5, 6], and is associated
80 with increased severity of disease [7-9].

81 In conjunction with water, sanitation, and hygiene (WASH) interventions, the World Health
82 Organization (WHO) recommends vaccines as an important tool in typhoid prevention and control [10].
83 The WHO prequalified the first typhoid conjugate vaccine (TCV), Typbar-TCV[®] (Bharat Biotech
84 International Limited, India), which comprises the Vi polysaccharide conjugated to tetanus toxoid, in
85 December 2017 for use in children as young as 6 months old [10]. A second TCV (TYPHIBEV[®], Biological
86 E. Limited, India) was prequalified in December 2020 [11]. Earlier typhoid vaccines, Ty21a and the
87 unconjugated Vi polysaccharide (ViPS) vaccine, are not recommend for infants and the ViPS vaccine is
88 not as immunogenic as TCVs [10]. In multiple studies, including randomized controlled trials, ranging
89 from infants to adults, TCVs have shown 79-95% efficacy in preventing typhoid fever [12-18], and earlier
90 analysis from this project measured a vaccine effectiveness of 82% in our sampled population [19].
91 Additionally, TCV can safely be co-administered with other routine vaccines without immune
92 interference or increased adverse events [20], making it ideal for inclusion in a country's routine
93 immunization schedule.

94 Navi Mumbai, India is an urban municipality outside of Mumbai administered by the Navi
95 Mumbai Municipal Corporation (NMMC). Prior observations suggested a high burden of typhoid in
96 children [21]. In 2018, the NMMC implemented the first phase of a public-sector pediatric TCV campaign

97 [22]. The campaign targeted all children aged 9-months through 14-years living within NMMC
98 boundaries (~320,000 children) over the course of 2 vaccination phases (each ~160,000 children). The
99 selection of areas to include in the two phases of the campaign were initially developed as a single step
100 wedge design randomized control trial in collaboration with NMMC. The first phase of the TCV mass
101 vaccination campaign occurred over the course of 6 weeks between 14 July and 25 August 2018, and
102 reached an estimated 113,420 children (71% of the target population); each child received one dose of
103 Typbar-TCV®. At the time of vaccination, each family received a TCV vaccination card to keep as a part of
104 their medical record. The second, delayed vaccination campaign was planned for 2020, but was
105 postponed due to the COVID-19 pandemic and has not yet been conducted. The first confirmed case of
106 COVID-19 was reported in India on January 30, 2020 [23] and a subsequent countrywide lockdown
107 started on March 25, 2020 .

108 While previous randomized clinical trial data provide safety and efficacy data, only in Pakistan
109 has TCV effectiveness been evaluated in a public sector, outbreak setting [15]. Our study provides the
110 first evaluation of a public sector mass vaccination campaign using TCV in a non-outbreak setting. This
111 information may be useful to key stakeholders and policymakers as decisions are made on whether to
112 introduce TCV into routine immunization programs through immunization campaigns in *S. Typhi*-
113 endemic countries.

114

115 **METHODS**

116 **Setting**

117 NMMC's administrative boundaries are divided into 22 areas of approximately even population
118 size, demarcated by the catchment areas of the city's 22 Urban Health Posts (UHPs). In conjunction with
119 NMMC, we stratified areas based on proportion of the population living in slums (stratum 1, <10%;
120 stratum 2, 10%-70%; and stratum 3, >70%) [22], and randomly assigned areas either to vaccine

121 campaign communities, which underwent the mass vaccination campaign in 2018, or delayed vaccine
122 campaign communities, which were to be included in the second phase of the vaccination campaign
123 (Figure 1). Children aged 9-months through 14-years were eligible for the vaccination campaign,
124 amounting to an estimated 320,000 children within the NMMC administrative boundaries, and an
125 estimated 160,000 children targeted for immunization in the first phase of the campaign.

126 **Design**

127 Original design and statistical analysis plan

128 We planned to estimate the incidence of blood culture-confirmed typhoid among children
129 eligible to receive the vaccine in the vaccine campaign communities and compare this to the delayed
130 campaign communities (<https://clinicaltrials.gov/ct2/show/NCT03554213>), following a single step
131 wedge design. We intended to deploy hybrid surveillance that adjusted the crude typhoid fever
132 incidence for healthcare utilization [24], utilizing prospective, blood culture-based surveillance at 6
133 hospitals and a continuous community survey. The COVID-19 pandemic radically altered healthcare
134 seeking behavior in Navi Mumbai and necessitated the suspension of the continuous community survey
135 to minimize risk to fieldworkers. But the healthcare facility blood culture surveillance continued
136 (September 1, 2018 through March 31, 2021) providing community-level blood culture data.

137

138 Revised design and statistical analysis plan

139 To evaluate the effectiveness of the mass vaccination campaign in the setting of radically altered
140 and reduced healthcare seeking, we implemented a test-negative case-control design [25]. Among
141 pediatric patients presenting with a febrile illness to affiliated healthcare sites, we identified cases as
142 being blood culture positive for *S. Typhi* and controls as being blood culture negative for *S. Typhi*, and

143 we then examined home address in a vaccine campaign community or a delayed campaign community
144 as the exposure of interest.

145

146 Inclusion Criteria

147 We included children within the age range of eligibility for the vaccination campaign (9-months
148 through 14-years), and through 16-years to account for aging during the follow up period, who
149 presented or were sent to a hospital sentinel site with a febrile illness (>3 days of fever within the past 7
150 days without upper respiratory tract symptoms and/or vesicular rash). The hospital sites were D.Y. Patil
151 Medical College and Hospital, Nerul; Dr. Yewale Multispecialty Hospital for Children, Vashi; Mahatma
152 Gandhi Memorial (MGM) New Bombay Hospital, Vashi; Mathadi Hospital Trust, Koparkharaine; NMMC
153 General Hospital, First Referral Unit (FRU), Vashi; and Rajmata Jijau Hospital, NMMC, Airoli. We offered
154 free blood culture to all participants who met the inclusion criteria. Participants were included for 33
155 months (September 1, 2018 – March 31, 2021).

156 Exclusion Criteria

157 Participants were excluded if no result was recorded for their blood culture or if they did not
158 have a place of residence listed or listed a location outside of NMMC boundaries.

159 **Data Analysis**

160 We matched each case with up to 3 controls on age (+/- 12 months) and time of enrollment (+/-
161 28 days) to account for age-related differences in typhoid incidence [1, 26, 27] and the seasonality of

162 typhoid fever in the region [28]. We attempted to match on shorter time intervals of enrollment, but
163 these failed to match all cases (R MatchIt Package,R version 4.0.4).

164 We performed conditional logistic regression (clogit function from R “survival” package, R
165 version 4.0.4) to estimate the odds that a blood culture-positive *S. Typhi* case resided in the vaccine
166 campaign communities versus the delayed vaccine campaign communities. We adjusted the model for
167 participant sex and education group (whether respondent has more than primary school education or
168 not). Programmatic campaign effectiveness was calculated as $(1 - \text{Odds Ratio}) \times 100$.

169 We performed stratified analyses by participant age group (<5 years of age versus ≥ 5 years of
170 age), to assess age-specific effectiveness of the vaccine, and by time since vaccine campaign (≤ 365 days
171 [September 1, 2018 – August 31, 2019] versus > 365 days [September 1, 2019 – March 31, 2021] since
172 phase 1 of the campaign) to evaluate any differences in effectiveness between the first and second-third
173 years after the campaign. These stratified analyses were both tested for the significance of the
174 difference by interaction, as calculated by an ANOVA test for the null versus an interaction model,
175 where the interaction terms were “(study community)*(age strata)” in the age stratified analysis and
176 (study community)*(time since vaccine campaign strata)” in the time since vaccine campaign stratified
177 analysis, where study community is defined by vaccine campaign communities versus delayed vaccine
178 campaign communities.

179 Ethics Statement

180 We obtained written informed consent from adult caregivers and verbal assent from pediatric
181 participants aged >12 years. The study protocol was approved by MGM New Bombay Hospital IRB,
182 Vashi, India; Institutional Ethics Committee, Indian Council of Medical Research – National Institute of

183 Cholera and Enteric Diseases (No. A-1/2020-IEC); WHO Research Ethics Review Committee
184 (ERC.0002923); and Stanford University IRB (IRB-39627).

185

186 **RESULTS**

187 During September 1, 2018 – March 31, 2021 (33 months), we enrolled 2,953 participants who
188 met the fever definition (Figure 2). There were a total of 81 blood-culture positive cases of typhoid.
189 After matching on date of test (+/- 28 days) and age (+/- 12 months), we included 319 participants in our
190 analysis (Table 1, Figure 1). Among the 81 blood culture-positive cases of *S.Typhi*, 36 were from the
191 vaccine campaign communities and 45 were from the delayed vaccine campaign communities. There
192 were 238 blood-culture negative controls, 153 from the vaccine campaign communities and 85 from the
193 delayed vaccine campaign communities. The mean age of the cases was 6.9 years and the matched
194 controls 6.8 years old. Females represented 40% of cases and 47% of matched controls.

195 The unadjusted odds ratio (OR) that culture-confirmed typhoid cases resided in the vaccine
196 campaign communities versus in the delayed vaccine campaign communities was 0.44 (95% CI: 0.27-
197 0.74; p-value = 0.002). The adjusted odds ratio (aOR) was 0.44 (95% CI: 0.26-0.75; p-value = 0.003),
198 indicating that the effectiveness of the mass vaccination campaign was 56% (95% CI: 25-74%) in the
199 vaccine campaign communities (Table 2).

200 When stratified by participant age group (< 5 years of age versus ≥ 5 years of age), amongst the
201 under 5 years participants, cases were 0.70 times as likely to live in vaccine campaign communities
202 compared with delayed vaccine campaign communities (campaign effectiveness, 30%, 95% CI: -110-76;
203 p-value = 0.5), while cases aged 5 years and older were 0.37 times as likely to live in vaccine campaign
204 communities (campaign effectiveness, 63%, 95% CI: 30-81; p-value = 0.002). When stratified by time
205 since campaign (≤ 365 days versus > 365 days since campaign), cases occurring within the first year after

206 the campaign were 0.30 times as likely to live in vaccine campaign communities (campaign
207 effectiveness, 70%, 95% CI: 36-86; p-value = 0.002), while cases identified during the second-third year
208 after the campaign were 0.75 times as likely to live in vaccine campaign communities (campaign
209 effectiveness, 25%, 95% CI: -70-67; p-value = 0.5).

210

211 **DISCUSSION**

212 The TCV campaign successfully vaccinated an estimated 113,420 children in 6 weeks. Typhoid
213 fever cases were 56% less likely to reside in vaccine campaign communities than in delayed vaccine
214 campaign communities. When stratified by age, older case-patients (>5 years old) were 63% less likely to
215 reside in vaccine campaign communities than delayed vaccine campaign communities, but this
216 difference was not significant when tested for the significance of the difference by interaction.
217 Additionally, when stratified by time since vaccine campaign surveillance, typhoid fever cases were 70%
218 less likely to live in the vaccine campaign communities during the first year of surveillance, but this
219 difference was also not significant when tested for the significance of the difference by interaction.

220 The overall programmatic effectiveness of the vaccination campaign on the reduction of typhoid
221 in the intervention community was consistent with 71% estimated vaccine coverage of an 82% effective
222 vaccine. Our crude and adjusted overall campaign effect odds ratios were similar, indicating that
223 adjustment for participant sex and respondent education had little impact, and these variables were
224 unlikely to be strong confounders.

225 To minimize risk to project fieldworkers from the COVID-19 pandemic, we halted the continuous
226 community survey. Since the original study design and statistical analysis plan did not allow for this
227 significant impact on data collection, and given the effect of the marked change in healthcare utilization
228 due to the COVID-19 pandemic, we could not follow the prespecified study design. Instead, utilizing the

229 available blood culture data, we employed a test-negative design to analyze our results [29, 30]. This
230 allowed us to evaluate the overall impact of the vaccine campaign on the reduction of typhoid cases
231 between the intervention communities versus the delayed vaccine campaign communities. This study
232 design, modeled off the popular test-negative design used in influenza [31], rotavirus [32], and COVID-
233 19 [33, 34] vaccine effectiveness studies, has been shown to be concordant with vaccine effectiveness
234 results from randomized controlled trials [25, 32]. The cluster randomized test-negative design has also
235 been utilized in the evaluation of dengue control interventions [35]. Recently, the WHO issued guidance
236 recommending the use of the test-negative design for COVID-19 vaccine effectiveness studies due to
237 logistical ease and reduction of health utilization bias [33, 34].

238 In addition to the unpredictable impact of the COVID-19 pandemic, this study is limited by
239 utilizing *S. Typhi* blood culture as the outcome measure for test-positive cases versus test-negative
240 controls. Blood culture sensitivity in detecting *S. Typhi* infection is estimated to be between 55-65% [1,
241 36] and is dependent on the blood volume collected [36], for which we do not have data. As such, blood
242 culture positivity as an outcome measure may result in underreporting of test-positive cases and loss of
243 statistical power, but this would be expected to affect both vaccine campaign and delayed vaccine
244 campaign communities and so would not bias the estimate of campaign effectiveness. For now, blood
245 culture remains the standard outcome utilized by evaluations of interventions to combat *S. Typhi*
246 infection in controlled trials and public health programs, and *S. Typhi* surveillance [1, 5, 6, 9, 13-15, 17,
247 18].

248 There are a number of descriptions in the literature of programmatic or outbreak
249 implementation of typhoid vaccines [15, 37-39]. However, formal assessment is limited and many lack a
250 systematically evaluated population control group, limiting generalizability [15, 37-39]. Our results
251 represent a metropolitan introduction of typhoid vaccine in which we systematically evaluated the

252 overall campaign effectiveness with control communities that had not yet undergone a TCV
253 immunization campaign. As compared to previous generation typhoid vaccines, unconjugated Vi
254 polysaccharide and Ty21a, TCVs induce consistently higher levels of protective efficacy and are indicated
255 for use in younger children [10]. TCVs provide more durable immune responses than do unconjugated Vi
256 polysaccharide vaccine, and are expected to have longer durations of protection than prior generation
257 typhoid vaccines [10, 16]. This study provides further evidence that TCVs are effective when rolled out in
258 the form of a municipal program.

259 Although the campaign did reduce typhoid, some children who lived in the intervention
260 community still developed typhoid, even some of those children who were vaccinated [19]. Effective
261 communication to stakeholders and policymakers should include the caveat that while programmatic
262 implementation of TCV in children and adolescents will reduce typhoid incidence, it is not likely to
263 interrupt all transmission and eliminate the disease for several reasons [14]. First, although highly
264 effective, typhoid vaccines are not 100% effective, as has been reported from individually randomized
265 trials [12-18]. Second, adults who are susceptible to typhoid, are not usually included in typhoid
266 immunization campaigns or programs. These adults sometimes develop typhoid fever and transmit *S.*
267 *Typhi*. Even the targeted age groups are unlikely to be fully reached by vaccine campaigns – in this study
268 vaccine coverage was an estimated 71%. Finally, vaccination will not cure *S. Typhi* chronic carriers, who
269 will remain a reservoir for future transmission. Thus, public health planners should be prepared to
270 communicate that TCV reduces but does not eliminate risk, and increased attention to providing food
271 and drinking water not contaminated with feces will be important to reduce typhoid-associated
272 morbidity and mortality.

273 Our findings support the use of TCV mass vaccination campaigns as an effective population-
274 based tool to reduce the pediatric public health burden of typhoid fever, as part of the introduction of

275 TCV into routine immunization programs. This evaluation adds to the body of research supporting TCV
276 campaigns by demonstrating these campaigns can be effective at the population level, while prior
277 modeling suggests they may be highly cost-effective [40]. Additionally, our experience is in the setting of
278 atypical population healthcare utilization or low reported typhoid incidence, the test-negative design is
279 useful in estimating programmatic campaign effectiveness. Our data adds to the growing evidence that
280 stakeholders can use to support decisions on TCV introduction to reduce the burden of typhoid fever.

281

282 **FUNDING**

283 This work was supported by Bill and Melinda Gates Foundation Grant #OPP1169264 (PI: Prof. Stephen P.
284 Luby).

285

286 **ACKNOWLEDGEMENTS**

287 We thank the following organizations and individuals for their contributions to this evaluation: the Navi
288 Mumbai Municipal Corporation leadership and staff, the Government of India Ministry of Health and
289 Family Welfare Universal Immunization Program, State of Maharashtra Department of Public Health and
290 Family Welfare, Indian Academy of Pediatrics Navi Mumbai Chapter, Bharat Biotech International
291 Limited, the Indian Council of Medical Research, WHO-India National Public Health Surveillance Project,
292 the Navi Mumbai Municipal Corporation Hospital (Dr. Savita Daruwalla), D.Y. Patil Medical College and
293 Hospital (Dr. Rajesh Rai, Dr. Keertana Shetty), Mathadi Trust Hospital (Dr. Divya Warriar), MGM New
294 Bombay Hospital Vashi (Dr. Jeetendra Gavhane, Dr. Shalini Yadav), Dr. Yewale Multi-Specialty Hospital
295 for Children (Dr. Dhanya Dharmapalan), Grant Government Medical College (Dr. Nilma Hirani), Dr.
296 Joshi's Central Clinical Microbiology Laboratory, Vashi (Dr. Shrikrishna Joshi), Rajmata Jijau Hospital,

297 NMMC, Airoli (Dr. Varsha Rathod), and the Centers for Disease Control and Prevention, Atlanta, Georgia
298 (Dr. Kathleen Wannemuehler, Benjamin Nygren, and Matt Mikoleit).

299 **DISCLAIMER**

300 The findings and conclusions in this report are those of the authors and do not necessarily represent the
301 official position, policies, or views of the United States Centers for Disease Control and Prevention, or
302 the World Health Organization.

303 **POTENTIAL CONFLICTS OF INTEREST**

304 All authors report no conflicts of interest

305

306 **REFERENCES**

307

- 308 1. GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and
309 paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*
310 *Infect Dis* **2019**; 19(4): 369-81.
- 311 2. Woodward TE, Smadel JE. Management of Typhoid Fever and Its Complications. *Ann Intern Med*
312 **1964**; 60(1): 144-57.
- 313 3. Marmion DE. The treatment of typhoid fever with chloramphenicol; a clinical study of 330 cases
314 of enteric fever treated in Egypt. *Trans R Soc Trop Med Hyg* **1952**; 46(6): 619-38.
- 315 4. Woodward TE, Smadel JE, Parker RT, Wisseman CL, Jr. Treatment of typhoid fever with
316 antibiotics. *Ann N Y Acad Sci* **1952**; 55(6): 1043-55.
- 317 5. Qamar FN, Yousafzai MT, Dehraj IF, et al. Antimicrobial Resistance in Typhoidal Salmonella:
318 Surveillance for Enteric Fever in Asia Project, 2016–2019. *Clin Infect Dis* **2020**;
319 71(Supplement_3): S276-S84.

- 320 6. Samajpati S, Pragasam AK, Mandal S, Balaji V, Dutta S. Emergence of ceftriaxone resistant
321 Salmonella enterica serovar Typhi in Eastern India. *Infect Genet Evol* **2021**: 105093.
- 322 7. Bhutta ZA. Impact of age and drug resistance on mortality in typhoid fever. *Arch Dis Child* **1996**;
323 75(3): 214-7.
- 324 8. Walia M, Gaiind R, Mehta R, Paul P, Aggarwal P, Kalaivani M. Current perspectives of enteric
325 fever: a hospital-based study from India. *Ann Trop Paediatr* **2005**; 25(3): 161-74.
- 326 9. Longley AT, Hemlock C, Date K, et al. Illness Severity and Outcomes Among Enteric Fever Cases
327 From Bangladesh, Nepal, and Pakistan: Data From the Surveillance for Enteric Fever in Asia
328 Project, 2016–2019. *Clin Infect Dis* **2020**; 71(Supplement_3): S222-S31.
- 329 10. WHO. Typhoid vaccines: WHO position paper, March 2018 - Recommendations. *Vaccine* **2019**;
330 37(2): 214-6.
- 331 11. Birkhold M, Mwisongo A, Pollard AJ, Neuzil KM. Typhoid Conjugate Vaccines: Advancing the
332 Research and Public Health Agendas. *J Infect Dis* **2021**; 224(12 Suppl 2): S781-s7.
- 333 12. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-
334 five-year-old children. *N Engl J Med* **2001**; 344(17): 1263-9.
- 335 13. Shakya M, Colin-Jones R, Theiss-Nyland K, et al. Phase 3 Efficacy Analysis of a Typhoid Conjugate
336 Vaccine Trial in Nepal. *N Engl J Med* **2019**; 381(23): 2209-18.
- 337 14. Qadri F, Khanam F, Liu X, et al. Protection by vaccination of children against typhoid fever with a
338 Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. *Lancet*
339 **2021**; 398(10301): 675-84.
- 340 15. Yousafzai MT, Karim S, Qureshi S, et al. Effectiveness of typhoid conjugate vaccine against
341 culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak
342 setting of Hyderabad, Pakistan: a cohort study. *Lancet Glob Health* **2021**; 9(8): e1154-e62.
- 343 16. Vadrevu KM, Raju D, Rani S, et al. Persisting antibody responses to Vi polysaccharide-tetanus
344 toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of
345 children < 2 years of age with, or without, a booster vaccination. *Vaccine* **2021**; 39(45): 6682-90.
- 346 17. Patel PD, Patel P, Liang Y, et al. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian
347 Children. *N Engl J Med* **2021**; 385(12): 1104-15.

- 348 18. Shakya M, Voysey M, Theiss-Nyland K, et al. Efficacy of typhoid conjugate vaccine in Nepal: final
349 results of a phase 3, randomised, controlled trial. *Lancet Glob Health* **2021**; 9(11): e1561-e8.
- 350 19. Date K, Harvey P, Bhatnagar P, et al. Field effectiveness of a typhoid conjugate vaccine — Navi
351 Mumbai (India), 2018-2020. *American Society of Tropical Medicine and Hygiene 2020 National*
352 *Meeting*. Arlington, VA, **2020**.
- 353 20. Sirima SB, Ouedraogo A, Barry N, et al. Safety and immunogenicity of co-administration of
354 meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children
355 aged 15-23 months in Burkina Faso. *Int J Infect Dis* **2021**; 102: 517-23.
- 356 21. Gavhane J, Yewale V, Weekey P, Dhanya, Warrior D. Enteric Fever in children from Navi Mumbai
357 — Clinical Profile, Hematological features, Sensitivity Patterns and Response to Antimicrobials.
358 *Pediatr Infect Dis* **2010**; 2(1): 5-9.
- 359 22. Date K, Shimpi R, Luby S, et al. Decision Making and Implementation of the First Public Sector
360 Introduction of Typhoid Conjugate Vaccine—Navi Mumbai, India, 2018. *Clin Infect Dis* **2020**;
361 71(Supplement_2): S172-S8.
- 362 23. Andrews MA, Areekal B, Rajesh KR, et al. First confirmed case of COVID-19 infection in India: A
363 case report. *Indian J Med Res* **2020**; 151(5): 490-2.
- 364 24. Andrews JR, Barkume C, Yu AT, et al. Integrating Facility-Based Surveillance With Healthcare
365 Utilization Surveys to Estimate Enteric Fever Incidence: Methods and Challenges. *J Infect Dis*
366 **2018**; 218(suppl_4): S268-s76.
- 367 25. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy
368 and precision of vaccine efficacy estimates compared to the gold standard of randomised
369 placebo-controlled clinical trials. *Euro Surveill* **2013**; 18(37).
- 370 26. Sinha A, Sazawal S, Kumar R, et al. Typhoid fever in children aged less than 5 years. *Lancet* **1999**;
371 354(9180): 734-7.
- 372 27. Walia M, Gaiind R, Paul P, Mehta R, Aggarwal P, Kalaivani M. Age-related clinical and
373 microbiological characteristics of enteric fever in India. *Trans R Soc Trop Med Hyg* **2006**; 100(10):
374 942-8.
- 375 28. Saad NJ, Lynch VD, Antillón M, Yang C, Crump JA, Pitzer VE. Seasonal dynamics of typhoid and
376 paratyphoid fever. *Sci Rep* **2018**; 8(1): 6870.

- 377 29. Anders KL, Cutcher Z, Kleinschmidt I, et al. Cluster-Randomized Test-Negative Design Trials: A
378 Novel and Efficient Method to Assess the Efficacy of Community-Level Dengue Interventions.
379 *Am J Epidemiol* **2018**; 187(9): 2021-8.
- 380 30. Jewell NP, Dufault S, Cutcher Z, Simmons CP, Anders KL. Analysis of cluster-randomized test-
381 negative designs: cluster-level methods. *Biostatistics* **2019**; 20(2): 332-46.
- 382 31. Jackson ML, Chung JR, Jackson LA, et al. Influenza Vaccine Effectiveness in the United States
383 during the 2015-2016 Season. *N Engl J Med* **2017**; 377(6): 534-43.
- 384 32. Schwartz LM, Halloran ME, Rowhani-Rahbar A, Neuzil KM, Victor JC. Rotavirus vaccine
385 effectiveness in low-income settings: An evaluation of the test-negative design. *Vaccine* **2017**;
386 35(1): 184-90.
- 387 33. World Health Organization. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17
388 March 2021. Geneva: World Health Organization, **2021** 2021.
- 389 34. Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-introduction COVID-19 vaccine
390 effectiveness: Summary of interim guidance of the World Health Organization. *Vaccine* **2021**;
391 39(30): 4013-24.
- 392 35. Utarini A, Indriani C, Ahmad RA, et al. Efficacy of Wolbachia-Infected Mosquito Deployments for
393 the Control of Dengue. *N Engl J Med* **2021**; 384(23): 2177-86.
- 394 36. Mogasale V, Ramani E, Mogasale VV, Park J. What proportion of Salmonella Typhi cases are
395 detected by blood culture? A systematic literature review. *Ann Clin Microbiol Antimicrob* **2016**;
396 15(1): 32.
- 397 37. Yang HH, Kilgore PE, Yang LH, et al. An outbreak of typhoid fever, Xing-An County, People's
398 Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid
399 vaccine. *J Infect Dis* **2001**; 183(12): 1775-80.
- 400 38. Khan MI, Ochiai RL, Clemens JD. Population impact of Vi capsular polysaccharide vaccine. *Expert*
401 *Rev Vaccines* **2010**; 9(5): 485-96.
- 402 39. Nga TVT, Duy PT, Lan NPH, Chau NVV, Baker S. The Control of Typhoid Fever in Vietnam. *Am J*
403 *Trop Med Hyg* **2018**; 99(3_Suppl): 72-8.

- 404 40. Ryckman T, Karthikeyan AS, Kumar D, et al. Comparison of Strategies for Typhoid Conjugate
405 Vaccine Introduction in India: A Cost-Effectiveness Modeling Study. *J Infect Dis* **2021**;
406 224(Supplement_5): S612-S24.
407
408

409 TABLES

410 Table 1: Demographic characteristics of child participants and adult respondents

	Blood-culture positive cases (N=81)	Blood-culture negative controls (N=238)	P-value
Child Age			
Mean (SD)	6.85 (3.54)	6.77 (3.54)	0.9
Median [Min, Max]	7.00 [1.00, 15.0]	7.00 [1.00, 15.0]	
Child Gender			
Male	49 (60.5%)	127 (53.4%)	0.3
Female	32 (39.5%)	111 (46.6%)	
Adult Respondent Gender			
Male	38 (46.9%)	122 (51.3%)	0.5
Female	42 (51.9%)	113 (47.5%)	
Missing	1 (1.2%)	3 (1.3%)	
Adult Respondent Age			
Mean (SD)	34.9 (7.43)	34.6 (8.66)	0.7
Median [Min, Max]	35.0 [19.0, 59.0]	34.0 [18.0, 85.0]	
Missing	0 (0%)	1 (0.4%)	
Adult Respondent Education Level			
Primary school certificate (through Grade 4) or less	6 (7.4%)	32 (13.4%)	0.1
Middle school certificate (Grade 5 - 10)	35 (43.2%)	112 (47.1%)	
High school certificate (Grade 11 - 12)	14 (17.3%)	45 (18.9%)	
Bachelors degree or greater	25 (30.9%)	49 (20.6%)	
Don't know or refused	1 (1.2%)	0 (0%)	

411
412
413
414
415
416
417
418
419

420 **Table 2. Overall and Stratified Campaign Effectiveness**

421

	Odds Ratio	Campaign Effectiveness (%)	P-value
Overall campaign effectiveness	0.44 (0.26, 0.75)	56% (25, 74)	0.003
Stratified by age			
< 5 years (case n=21, control n=64)	0.70 (0.24, 2.10)	30% (-110, 76)	0.5
≥ 5 years (case n=60, control n=174)	0.37 (0.19, 0.70)	63% (30, 81)	0.002
Stratified by time since vaccination campaign			
≤ 365 days (case n=45, control n=135)	0.30 (0.14, 0.64)	70% (36, 86)	0.002
> 365 days (case n=36, control n=103)	0.75 (0.33, 1.70)	25% (-70, 67)	0.5

422

423

424

425

426

427

428

429

430

431


432

433

434

435 FIGURES

436 Figure 1. Map of vaccine campaign and delayed campaign communities



437

438


439

440

441

442 **Figure 2. Trial Profile**

443



444

445

446

447

448

449

450

451

452

453 **FIGURE LEGENDS**

454 **Figure 1.** Map of vaccine campaign communities (blue stripes) and delayed campaign communities
455 (yellow solid) as demarcated by the borders of Navi Mumbai Municipal Corporation's 22 Urban Health
456 Posts. Hospitals that participated in healthcare facility blood culture surveillance marked by green
457 circles.

458
459 **Figure 2.** Flow diagram depicting total estimated eligible participant population in Navi Mumbai
460 (~320,000), number of participants reported by healthcare facility blood culture surveillance (4,602),
461 number of participants with complete records (2,953), number of participants included in analysis after
462 matching (319), and blood culture positive and negatives included in analysis.

463

464

465